Neurotech International has reported more positive results from pre-clinical trials of its proprietary cannabis treatment for multiple sclerosis (MS).
Results demonstrated the ability of Neurotech’s NTI/Dolce strains to suppress or inhibit the occurrence of COX-2, the main enzyme that causes inflammation in MS patients.
The company said the strains were up to three times more powerful in suppressing COX-2 in human-derived microglial cells than CBD alone.
Previous studies showed that when applied to other MS neuro-markers GM-CSF and TNF Alpha, the strains showed a material suppression of 40% and 30% respectively, compared to CBD alone, which had no significant effect
NTI chairman Brian Leedman told Stockhead: “These results re-confirm the potent anti-inflammatory properties of NTI/Dolce strains and provide further evidence for their development as neuro anti-inflammatory therapies across a number of neuro diseases.”
The next stage of the pre-clinical trial program will involve comparison of NTI/Dolce strains with current pharmaceutical treatment options, which can cause multiple side-effects.
